Sustentación de Tesis, Estudiante: LUISA FERNANDA RODRÍGUEZ VALLEJO

Value of the Information & Strength of the Argument

The value of the information is high, as it addresses a significant gap in pharmacogenetic research for underrepresented populations. The argumentation is solid, systematically explaining the rationale for selecting the specific genes and variants, supported by evidence from clinical studies and databases like PharmGKB. The presentation effectively argues for the necessity of local genetic characterization to improve drug response predictions. The logical flow from the importance of pharmacogenetics to the specific research question and methodology is clear and compelling.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is commendable, with a well-defined research question and methodology. The sources cited include relevant literature and databases, though specific references are not explicitly listed in the video. The title accurately reflects the content, and the presentation adheres to academic standards. The use of established pharmacogenetic guidelines and the acknowledgment of limitations in current knowledge enhance the credibility. The adequacy between title and content is excellent, with no discrepancies.

The title accurately reflects the content, which focuses on determining allelic and genotypic frequencies of eight variants in five genes across three Colombian ethnic groups.

8/10

The thesis defense presents a well-structured original study on pharmacogenetic variants in Colombian ethnic groups. The methodology is clearly described, and the research is grounded in established scientific literature. The presentation is rigorous, with appropriate citations and a clear research question. Minor limitations include the lack of detailed statistical analysis in the presentation and the reliance on self-reported ethnicity.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to the thesis defense and the research topic.
• 10:00Explanation of pharmacogenetics and its importance in drug response.
• 20:00Discussion on the genetic diversity of Colombian population and the need for local studies.
• 30:00Overview of the specific genes and variants selected for the study.
• 40:00Detailed description of the metabolic pathways of cytarabine and anthracyclines.
• 50:00Presentation of the research question and objectives.
• 1:00:00Methodology: study design, sample collection, and genotyping methods.
• 1:10:00Preliminary results and statistical analysis.
• 1:20:00Discussion of the implications of the findings for pharmacogenetics in Colombia.
• 1:30:00Conclusion and future directions.

• PharmGKB — Referenced as a key resource for pharmacogenetic variant interpretation and clinical guidelines.
• 1000 Genomes Project — Mentioned as a common source of genetic data, but criticized for its limited representation of Colombian populations.

• PharmGKB — Supports the clinical relevance of the selected variants and provides guidelines for drug dosing.

• 1000 Genomes Project — The presenter argues that the Colombian samples in 1000 Genomes are not representative of the country's diverse population, thus questioning the applicability of its data for pharmacogenetic studies in Colombia.